Treatment of malignant ventricular arrhythmias in man with an implanted automatic defibrillator.

M. Mirowski,M. Mower,P. R. Reid

DOI: https://doi.org/10.1097/00003246-198105000-00018

IF: 8.8

1981-05-01

Critical Care Medicine

Abstract:

What problem does this paper attempt to address?

Use of the automatic implantable cardioverter-defibrillator in the treatment of malignant ventricular tachyarrhythmias

M Mirowski,P R Reid,M M Mower,L Watkins Jr,E V Platia,L S Griffith,J M Juanteguy

Herz

Abstract:Since February, 1980 nearly 200 automatic cardioverter - defibrillators have been implanted in patients with malignant ventricular arrhythmias. The currently-employed device weighs 298 grams and occupies a volume of 162 cm3. There are two defibrillation electrodes which also serve as sensors: one, an intravascular catheter placed in the superior vena cava at the level of the right atrium; the other, a flexible rectangular patch placed extrapericardially over the apex of the heart. Additionally, there is a bipolar right ventricular electrode for rate counting and R-wave synchronization which will eventually be used for pacing as well. The unit is powered by lithium batteries with a projected monitoring life of three years, or the capability of discharging approximately 100 times. The arrhythmia detector activates the cardioverter -defibrillator about 15 to 20 seconds after diagnosing a "treatable" arrhythmia, identified on the basis of a striking absence of isoelectric potential segments characteristic of ventricular fibrillation and many ventricular tachycardias. The diagnosis also requires fulfillment of individually-programmed heart rate criteria. If the initial discharge of 25 joules is ineffective, the device will recycle as many as three times with a final pulse of up to 42 joules. Of the twelve nonsurvivors among the initial 52 implantees who underwent implantation through September, 1982, only four deaths were unwitnessed and considered to be sudden and arrhythmic; the other eight deaths were due to heart failure or unrelated causes. Thus, from a predicted mortality of 48% in the same group of patients if the automatic defibrillator had not been implanted, the "sudden death" mortality was reduced to 8.5%.
Potential Maintenance Mechanism in Atrial Fibrillation Patients Subject to Different Treatment Procedures: A Preliminary Study Based on a Human Atrial Model

Zhao-lian Ouyang,Li-ping Sun,Hui Chi,Ling Xia,Ying-lan Gong,Yu-bo Fan

DOI: https://doi.org/10.1007/s11596-018-1895-0

2018-01-01

Current Medical Science

Abstract:Two clinical ablation protocols, 2C3L and stepwise, have been routinely used in our group to treat atrial fibrillation (AF), but with a less than 60% long-term arrhythmia-free outcome achieved in patients. The goal of this study was to examine the underlying mechanism of low success in clinical outcome. MRI images from one patient were used to reconstruct a human atrial anatomical model, and fibrotic tissue was manually added to represent the arrhythmia substrate. AF was induced with standard protocols used in clinical practice. 2C3L and stepwise were then used to test the efficacy of arrhythmia termination in our model. The results showed that re-entries induced in our model could not be terminated by using either 2C3L or the stepwise protocol. Although some of the induced re-entries were terminated, others emerged in new areas. Ablation using only the 2C3L or stepwise method was not sufficient to terminate all re-entries in our model, which may partially explain the poor long-term arrhythmiafree outcomes in clinical practice. Our findings also suggest that computational heart modelling is an important tool to assist in the establishment of optimal ablation strategies.
[The implantable automatic cardioverter-defibrillator]

H Klein,J Tröster,H J Trappe,I Becht,F Siclari

Herz

Abstract:In addition to medical treatment for ventricular tachyarrhythmias which has not proven to be sufficient, nonmedical modes of treatment are available such as electrophysiologically-guided surgical measures and catheter ablation, both of which are restricted to only a relatively small patient population and require further technical refinement. In 1980, Mirowski introduced the automatic implantable defibrillator and, to date, world-wide, this device has been implanted in 8000 patients. CHARACTERISTICS AND IMPLANTATION OF THE AUTOMATIC IMPLANTABLE CARDIOVERTER/DEFIBRILLATOR (AICD): The AICD continuously monitors the electrical activity of the heart, recognizes the onset of threatening ventricular tachycardias and terminates these according to the respectively programmed mode by delivering direct current shocks or stimuli. The currently used defibrillators consist of an impulse generator with lithium batteries and an electrode system. The batteries can charge a capacitor with about 700 volts in five to eight seconds which produces a current with an energy up to 30 Joules on discharge. The current is delivered either by two plate electrodes on the right and left ventricles or a plate electrode on the left ventricle and a spiral electrode inserted in the superior vena cava. The electrodes also serve the purpose of tachycardia detection by means of an electrical signal, the probability density function (PDF), that is, a significant decrease in the potentials to isoelectric. With this, it is only possible to terminate ventricular fibrillation. Additional electrical detection criteria are obtained and analyzed by two adjacently positioned epicardial screw electrodes or a bipolar endocardial electrode, enable identification of ventricular tachycardia as well. If the tachycardia detection criteria are fulfilled, the capacitor is discharged according to its programmed shock energy. In 1988, programmable defibrillators were introduced. Current defibrillator treatment also incorporates the possibility for antitachycardia stimulation. Attempts to use, instead of the monophase, square-wave impulse, a biphasic defibrillation impulse, to achieve a sequential impulse and to make use of the bidirectional impulse extension have rendered improved reliability for tachycardia termination and energy savings. After median sternotomy, the plate electrodes are usually sutured to the epicardium and the spiral electrode for the bipolar ECG is positioned at the anterior aspect of the right ventricle. The generator is implanted on the left side para-umbilically in subcutaneous or subfascial tissue. With the subxyphoid approach to avoid sternotomy, the plate electrode is sutured extrapericardially over the left ventricle and the spiral electrode is positioned at the epicardium. Alternatively, for those in whom prior cardiac surgery has been carried out, a lateral thoracotomy can be used. The defibrillation threshold, that is the lowest possible energy for defibrillation of ventricular fibrillation or ventricular tachycardia, should be determined intraoperatively after stimulation of the arrhythmia. The energy required for termination of a stable ventricular tachycardia is usually less than that for termination of ventricular fibrillation and can be determined postoperatively. A margin of security should be taken into consideration which, for defibrillation thresholds of up to 10 Joules, is about twice the amount of the defibrillation threshold itself.(ABSTRACT TRUNCATED AT 400 WORDS)
The development of the extravascular defibrillator with substernal lead placement: A new Frontier for device-based treatment of sudden cardiac arrest

Amy E Thompson,Brett Atwater,Lucas Boersma,Ian Crozier,Gregory Engel,Paul Friedman,J Rod Gimbel,Bradley P Knight,Jaimie Manlucu,Francis Murgatroyd,David O'Donnell,Juergen Kuschyk,Paul DeGroot

DOI: https://doi.org/10.1111/jce.15511

Abstract:Introduction: The extravascular implantable cardioverter-defibrillato (EV ICD) system with substernal lead placement is a novel nontransvenous alternative to current commercially available ICD systems. The EV ICD provides defibrillation and pacing therapies without the potential long-term complications of endovascular lead placement but requires a new procedure for implantation with a safety profile under evaluation. Methods: This paper summarizes the development of the EV ICD, including the preclinical and clinical evaluations that have contributed to the system and procedural refinements to date. Results: Extensive preclinical research evaluations and four human clinical studies with >140 combined acute and chronic implants have enabled the development and refinement of the EV ICD system, currently in worldwide pivotal study. Conclusion: The EV ICD may represent a clinically valuable solution in protecting patients from sudden cardiac death while avoiding the long-term consequences of transvenous hardware. The EV ICD offers advantages over transvenous and subcutaneous systems by avoiding placement in the heart and vasculature; relative to subcutaneous systems, EV ICD requires less energy for defibrillation, enabling a smaller device, and provides pacing features such as antitachycardia and asystole pacing in a single system.
Ventricular Arrhythmias in Ischemic Cardiomyopathy—New Avenues for Mechanism-Guided Treatment

Matthew Amoni,Eef Dries,Sebastian Ingelaere,Dylan Vermoortele,H. Llewelyn Roderick,Piet Claus,Rik Willems,Karin R. Sipido

DOI: https://doi.org/10.3390/cells10102629

IF: 6

2021-10-01

Cells

Abstract:Ischemic heart disease is the most common cause of lethal ventricular arrhythmias and sudden cardiac death (SCD). In patients who are at high risk after myocardial infarction, implantable cardioverter defibrillators are the most effective treatment to reduce incidence of SCD and ablation therapy can be effective for ventricular arrhythmias with identifiable culprit lesions. Yet, these approaches are not always successful and come with a considerable cost, while pharmacological management is often poor and ineffective, and occasionally proarrhythmic. Advances in mechanistic insights of arrhythmias and technological innovation have led to improved interventional approaches that are being evaluated clinically, yet pharmacological advancement has remained behind. We review the mechanistic basis for current management and provide a perspective for gaining new insights that centre on the complex tissue architecture of the arrhythmogenic infarct and border zone with surviving cardiac myocytes as the source of triggers and central players in re-entry circuits. Identification of the arrhythmia critical sites and characterisation of the molecular signature unique to these sites can open avenues for targeted therapy and reduce off-target effects that have hampered systemic pharmacotherapy. Such advances are in line with precision medicine and a patient-tailored therapy.

cell biology
First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial

Roderick Tung,Yumei Xue,Minglong Chen,Chenyang Jiang,Dalise Y. Shatz,Stephanie Besser,Hongde Hu,Fa-Po Chung,Shiro Nakahara,Young-Hoon Kim,Kazuhiro Satomi,Lishui Shen,Erpeng Liang,Hongtao Liao,Kai Gu,Ruhong Jiang,Jian Jiang,Yuichi Hori,Jong-Il Choi,Akiko Ueda,Yuki Komatsu,Shuichiro Kazawa,Kyoko Soejima,Shih-Ann Chen,Akihiko Nogami,Yan Yao

DOI: https://doi.org/10.1161/CIRCULATIONAHA.122.060039

IF: 37.8

2022-01-01

Circulation

Abstract:BACKGROUND: Catheter ablation as first-line therapy for ventricular tachycardia (VT) at the time of implantable cardioverter defibrillator (ICD) implantation has not been adopted into clinical guidelines. Also, there is an unmet clinical need to prospectively examine the role of VT ablation in patients with nonischemic cardiomyopathy, an increasingly prevalent population that is referred for advanced therapies globally. METHODS: We conducted an international, multicenter, randomized controlled trial enrolling 180 patients with cardiomyopathy and monomorphic VT with an indication for ICD implantation to assess the role of early, first-line ablation therapy. A total of 121 patients were randomly assigned (1:1) to ablation plus an ICD versus conventional medical therapy plus an ICD. Patients who refused ICD (n=47) were followed in a prospective registry after stand-alone ablation treatment. The primary outcome was a composite end point of VT recurrence, cardiovascular hospitalization, or death. RESULTS: Randomly assigned patients had a mean age of 55 years (interquartile range, 46-64) and left ventricular ejection fraction of 40% (interquartile range, 30%-49%); 81% were male. The underlying heart disease was ischemic cardiomyopathy in 35%, nonischemic cardiomyopathy in 30%, and arrhythmogenic cardiomyopathy in 35%. Ablation was performed a median of 2 days before ICD implantation (interquartile range, 5 days before to 14 days after). At 31 months, the primary outcome occurred in 49.3% of the ablation group and 65.5% in the control group (hazard ratio, 0.58 [95% CI, 0.35-0.96]; P=0.04). The observed difference was driven by a reduction in VT recurrence in the ablation arm (hazard ratio, 0.51 [95%CI, 0.29-0.90]; P=0.02). A statistically significant reduction in both ICD shocks (10.0% versus 24.6%; P=0.03) and antitachycardia pacing (16.2% versus 32.8%; P=0.04) was observed in patients who underwent ablation compared with control. No differences in cardiovascular hospitalization (32.0% versus. 33.7%; hazard ratio, 0.82 [95% CI, 0.43-1.56]; P=0.55) or mortality (8.9% versus 8.8%; hazard ratio, 1.40 [95% CI, 0.38-5.22]; P=0.62]) were observed. Ablation-related complications occurred in 8.3% of patients. CONCLUSIONS: Among patients with cardiomyopathy of varied causes, early catheter ablation performed at the time of ICD implantation significantly reduced the composite primary outcome of VT recurrence, cardiovascular hospitalization, or death. These findings were driven by a reduction in ICD therapies.
Cause and Treatment of Inappropriate Therapy of Implantable Cardioverter Defibrillators

Dong-mei WANG,Ya-ling HAN,Hong-yun ZANG,Hai-bo YU,Xiao-guang WU,Shou-li WANG,Zu-lu WANG,Quan-min JING,Hong REN

DOI: https://doi.org/10.3760/cma.j.issn.1007-6638.2008.02.002

2008-01-01

Abstract:Objective The purpose of this study was to analyze the causes of inappropriate therapy and explore the treatment measure in patients with implantable cardioverter defibrillators (ICD). Methods Thirty four patients 24 men and 10 women, mean age (62. 54 ± 11.17) years received ICDs. Among these patients,21 received single-chamber ICD, 3 received double-chamber ICD and 10 received triple-chamber ICD (CRT-D).The mean follow-up duration were(20.72 ±16.89) months. Results Six(17.6%) patients (3 singlechamber ICD, 3 CRT-D) experienced inappropriate detections and therapies of ICD during follow-up. One patient with single-chamber ICD received an inappropriate shock due to myopotential interference (noise). The inappropriate shocks were caused by atrial fibrillation (AF) with rapid ventricular response reaching into ventricular fibrillation (VF) detect-zone in 4 patients. Device in the sixth patient with CRT-D (V350,ST. Jude Medical) detected supraventricular tachycardia (SVT) for 7 times. SVT were terminated by shocks after failed in ATPs when the lasting time of SVT was more than 60 seconds, because the longest time of discriminating SVT in device was 60 seconds. AF for 4 times in 2 patients is successfully terminated by ATP in FVT detectzone. Forty shocks 6 patients were caused by inappropriate detections, of which 14 occurred in single-chamber ICD and 26 occurred in triple-chamber ICD. The frequently shocks in a short time occurred in 6 patients. A patients received 7 shocks within 3 hours. Conclusions The rapid ventricular rate of AF in VF detect-zone was the main cause of inappropriate detections of ICD. Therefore control the ventricular rate of AF with medicine is important was patients with ICD. If the fast ventricular rate of AF is not controlled by medicine, the radiofrequency ablation of AF is the choice.
Management of ventricular tachycardia in patients with ischaemic cardiomyopathy: contemporary armamentarium

Ann-Kathrin Kahle,Christiane Jungen,Fares-Alexander Alken,Katharina Scherschel,Stephan Willems,Helmut Pürerfellner,Shaojie Chen,Lars Eckardt,Christian Meyer

DOI: https://doi.org/10.1093/europace/euab274

2022-04-05

Abstract:Worldwide, ∼4 million people die from sudden cardiac death every year caused in more than half of the cases by ischaemic cardiomyopathy (ICM). Prevention of sudden cardiac death after myocardial infarction by implantation of a cardioverter-defibrillator (ICD) is the most common, even though not curative, therapy to date. Optimized ICD programming should be strived for in order to decrease the incidence of ICD interventions. Catheter ablation reduces the recurrence of ventricular tachycardias (VTs) and is an important adjunct to sole ICD-based treatment or pharmacological antiarrhythmic therapy in patients with ICM, as conclusively demonstrated by seven randomized controlled trials (RCTs) in the last two decades. However, none of the conducted trials was powered to reveal a survival benefit for ablated patients as compared to controls. Whereas thorough consideration of an early approach is necessary following two recent RCTs (PAUSE-SCD, BERLIN VT), catheter ablation is particularly recommended in patients with recurrent VT after ICD therapy. In this context, novel, pathophysiologically driven ablation strategies referring to deep morphological and functional substrate phenotyping based on high-resolution mapping and three-dimensional visualization of scars appear promising. Emerging concepts like sympathetic cardiac denervation as well as radioablation might expand the therapeutical armamentarium especially in patients with therapy-refractory VT. Randomized controlled trials are warranted and on the way to investigate how these translate into improved patient outcome. This review summarizes therapeutic strategies currently available for the prevention of VT recurrences, the optimal timing of applicability, and highlights future perspectives after a PAUSE in BERLIN.
Transatlantic differences in the use of implantable cardioverter defibrillators in arrhythmogenic right ventricular cardiomyopathy

Perry Mark Elliott

DOI: https://doi.org/10.1093/eurheartj/ehae022

IF: 39.3

2024-01-30

European Heart Journal

Abstract:Graphical Abstract Schematic summarising the iterative, stepwise approach to risk stratification in ARVC. The dynamic nature of the disease requires regular reassessment of disease phenotype. Decisions on primary prevention implantable cardioverter defibrillators (ICDs) should take into account aetiology as well as putative clinical risk markers. In every case, shared decision making with respect to ICD therapy and life-style choices is essential. Schematic summarising the iterative, stepwise approach to risk stratification in ARVC. The dynamic nature of the disease requires regular reassessment of disease phenotype. Decisions on primary prevention implantable cardioverter defibrillators (ICDs) should take into account aetiology as well as putative clinical risk markers. In every case, shared decision making with respect to ICD therapy and life-style choices is essential.

cardiac & cardiovascular systems
Subcutaneous ICD Implantation and Catheter Ablation: A Step-Planned Approach for Ventricular Tachycardia Management in ARVC

Aurora Sanniti,Domenico Zagari,Elvira Renzullo,Chiara Valeriano,Paolo Moretti,Giammario Spadacini,Massimo Tritto

DOI: https://doi.org/10.1016/j.jaccas.2021.12.007

2022-02-16

Abstract:Secondary prevention of sudden cardiac death in the young patient with arrhythmogenic right ventricular cardiomyopathy and hemodynamically tolerated ventricular tachycardia is still a challenging field. We present a combined approach, including subcutaneous implantable cardioverter-defibrillator (ICD) and catheter ablation, as a promising treatment to prevent both ventricular tachycardia recurrences and ICD shocks. (Level of Difficulty: Intermediate.).
Tenth Annual Scientific Congress

Ngai‐Shing Mok,Chi-Chung Choy,N. Y. Chan,Andrew K.S. Ho,C. D. Fu,Michael Kang-Yin,M. Lee,Vincent Chan,S.S. Lau,Kathy Lai-Fun,Chu-Pak Lee,Kathy Lai‐Fun Lee,Gaoxing Zhang,Xuedong Shen,Shou-Yue Pu,Haozhu Chen

DOI: https://doi.org/10.55503/2790-6744.1188

2002-01-01

Abstract:Device therapy has become the preferred treatment for patients who have survived sudden cardiac death.Throughout the last decade, large-scale randomized clinical trials have provided consistent evidence on the clinical efficacy of device therapy.ICD is proven to be superior to anti-arrhythmic drugs in patients with structural heart diseases who suffer from haemodynamically significant ventricular arrhythmias.The role of ICD in primary prevention of sudden death in selected patients with coronary artery disease and left ventricular dysfunction is also widely established after the Multicenter Automatic Defibrillator Implant Trial (MADIT) 1 and the Multicenter Unsustained Tachycardia Trial (MUSTT). 2 In MADIT, patients with previous myocardial infarction, depressed left ventricular function (ejection fraction <35%) and non-sustained ventricular tachycardia underwent electrophysiology study.Among them, 196 patients with inducible sustained ventricular tachyarrhythmias but not suppressed by procainamide were randomized to receive an ICD or conventional therapy.The ICD group had a 54% reduction in mortality at 2 years, and the benefit was greatest in patients with the lowest left ventricular ejection fraction.The MUSTT trial was designed to compare electrophysiology-guided therapy and no active treatment in high-risk patients with
A cost-effective emergency room laboratory.

A. Portnoy,T. Kwiatkowski

1986-07-01

Abstract:
Prognosis in patients with coronary heart disease and ventricular arrhythmias received implantable cardioverter defibrillators

Dong-mei WANG,Ya-ling HAN,Hong-yun ZANG,Hai-bo YU,Shou-Li WANG,Zu-lu WANG,Quan-min JIN,Ying LIU

DOI: https://doi.org/10.3760/cma.j.issn.1007-6638.2008.03.011

2008-01-01

Abstract:Objective The purpose of this study was to observe long-term prognosis in patients with coronary heart disease(CHD) and fatal ventricular arrhythmias who underwent implantable cardioverter deilbrillators (ICD). Methods In 23 patients(age71.56 ± 10.38 years,18 male,16 cardiac insufficiency) ,ICD were implanted. Twenty patients received percutaneous coronary interventions(PCIs) ,2 patients received coronary artery bypass graft surgery(CABG). The patients suffered from syncope in 9, ventricular fibrillation (VF) in 5,sustained ventricular tachycardia(VT) in 22, of which 15patients received single-chamber ICDs (VVI), 1 received double-chamber ICDs(DDDR) ,and 7 received triple-chamber ICDs(CRT-D). The mean follow-up period was(33. 37 ±25.39)months. Results Two patients died for acute myocardial infarction or acute left heart failure respectively. Four patients accepted rehospitalization due to cardiac insufficiency, and electrical storm. During follow-up period, 13 patients (56. 5% )had sustained VT or VF events. Four-hundred and thirty-four sustained VT and 25 FVT episodes were recorded in all patients, majority of which were successfully terminated by antitachycardiac pacing. There were ICD electrical storms in 3 patients and inappropriate detection and thempies in 2 patients. Conclusions ICD therapies for patients with CHD and fatal ventricular arrhythmia after PCIs or CABG can prevent sudden death for VT( or VF)from myocardial chronic eicatricle.
Use of class IC antiarrhythmic drugs in patients with structural heart disease and implantable cardioverter defibrillator

Maura M. Zylla,Julian Wolfes,Ruben Schleberger,Dennis Lawin,Meinhard Kieser,Florian Reinke,Lars Eckardt,Andreas Rillig,Christoph Stellbrink,Dierk Thomas,Norbert Frey,Patrick Lugenbiel

DOI: https://doi.org/10.1007/s00392-024-02394-6

IF: 6.138

2024-02-20

Clinical Research in Cardiology

Abstract:Background Due to suspected pro-arrhythmic effects and increased mortality associated with class-IC antiarrhythmic drugs (AADs) in previous trials, AAD therapy in structural heart disease (SHD) is mainly restricted to amiodarone. In the presence of diagnostic and therapeutic advancements in cardiovascular medicine, it remains unclear if previous studies adequately reflect contemporary patients. In clinical practice, class-IC-AADs are occasionally used in individual cases, particularly in patients with an implantable cardioverter defibrillator (ICD). Methods This study retrospectively investigated outcome in ICD-carriers with SHD in whom class-IC-AADs were used as an individualized therapy due to failure, side effects, or unacceptable risk of alternative therapeutic options. Results Fifty patients from four tertiary centers were included (median age 48.5 years; 52% female). The most common underlying SHD were dilated (42%) or ischemic cardiomyopathy (26%) (median LVEF = 45%). Indications for AAD were sustained ventricular arrhythmias (VA) (58%), symptomatic premature ventricular contractions (26%), or atrial arrhythmias (16%). Median follow-up was 27.8 months. Freedom from sustained VA was 72%, and freedom from ICD therapy was 80%. In 19 patients (38%), AAD therapy was terminated. The most common reason was insufficient efficacy ( n = 8). Pro-arrhythmia was suspected in three patients. Five patients died during follow-up (10.0%), two of cardiovascular cause (4.0%). Conclusion In a multicenter cohort of ICD-carriers with SHD, class-IC-AADs were associated with a low rate of pro-arrhythmic effects or cardiovascular mortality. The majority of patients remained free from sustained VA during a follow-up of > 2 years. Further efforts should be made to evaluate the safety of class-IC-AADs in SHD patients receiving contemporary cardiovascular therapy.

cardiac & cardiovascular systems
Defibrillator implantation for the primary prevention of sudden cardiac death in patients with chronic heart failure

Hong-xia GUO,Wei XU,Xiao-hong LI,Wen-qing JI,Hong-song YU,Wen-cheng DI,Guang-fei SHI,Biao XU

DOI: https://doi.org/10.3760/cma.j.issn.1007-6638.2009.04.002

2009-01-01

Abstract:Objective,To assess the eficacy of implantable cardioveter defibrillator(ICD)for primary prevention of sudden cardiac death in patients with heart failure.Methods Patients accepted ICD implantation for primary prevention were enrolled from January 2005 until December 2008.All ICD interventions were classified ag ventricular tachycardia(VT),ventricular fibrillation(VF).Anti-tachycardia parameters were standardized.ATP and shock therapy were provided for VT and VF zone.Antiarrhythmic drug was prescribed after ICD implantation.Follow-up Was performed every 3～6 months after implantation and stored arrhythmic episedes and anti-tachycardia therapies documentation was used to clarify the character of treated tachyeardia.Resuits A total of 22 patients were follow-up for(12.8±8.6)months.The incidences of VT and VF were documented in 10 patients and received appropriate defibrillator therapies.Conclusion ICD therapy has efficacy in prevention for sudden cardiac death in patients with heart failure.
Radiofrequency Ablation of Ventricular Fibrillation and Multiple Right and Left Atrial Tachycardia in a Patient with Brugada Syndrome

Jean-Philippe Darmon,Salah Bettouche,Philippe Deswardt,Fabrice Tiger,Philippe Ricard,François Bernasconi,Nadir Saoudi

DOI: https://doi.org/10.1023/b:jice.0000048571.19462.54

2004-12-01

Journal of Interventional Cardiac Electrophysiology

Abstract:Brugada syndrome is a well-known form of idiopathic ventricular fibrillation (VF). Few data suggest that this arrhythmia may be triggered by ventricular premature beats (VPBs), and an association with other arrhythmia such as monomorphic ventricular tachycardia (VT) or supraventricular tachycardia (SVT) has been reported. In a highly symptomatic 18-year-old-male patient with this syndrome, frequent episodes of VF, fast polymorphic VT, and fast monomorphic sustained regular tachycardia were observed. The tachycardia episodes were classified as VT or VF and as a consequence received appropriate therapies with the implanted cardioverter defibrillator (ICD). Precipitating VPBs that were stored in the ICD memory and on the electrocardiogram (ECG) exhibited the same morphology as frequent isolated VPBs. During the electrophysiological study, right and left atrial tachycardia (AT) with one-to-one atrioventricular conduction were also induced and successfully ablated. VF was ablated using the same noncontact mapping (NCM) system triggering VPBs from right ventricular outflow tract (RVOT).

cardiac & cardiovascular systems
Anesthetic management of a patient with celiac disease.

S. Boynes,P. Moore,Craig J Shepherd,C. R. Bennett

DOI: https://doi.org/10.1016/J.TRIPLEO.2004.10.019

2005-02-01

Abstract:
The point on the treatment of arrhythmic storm

Ludovico Lazzari,Stefano Donzelli,Alessandra Tordini,Antonio Parise,Ciro Pirozzi,Federica Di Meo,Carmine Marallo,Vincenzo Pace,Chiara Marini,Giovanni Carreras

DOI: https://doi.org/10.1093/eurheartjsupp/suae016

2024-04-01

European Heart Journal Supplements

Abstract:Abstract Arrhythmic storm is a clinical emergency associated with high mortality, which requires multi-disciplinary management. Reprogramming of the implantable cardiac defibrillator (ICD) aimed at reducing shocks, adrenergic blockade using beta-blockers, sedation/anxiolysis, and blockade of the stellate ganglion represent the first simple and effective manoeuvres, but further suppression of arrhythmias with antiarrhythmics is often required. A low-risk patient (e.g. monomorphic ventricular tachycardia, functioning ICD, and haemodynamically stable) should be managed with a beta-blocker (possibly non-selective) plus amiodarone, in addition to sedation with a benzodiazepine or dexmedetomidine; in patients at greater risk (high burden and haemodynamic instability), autonomic modulation with blockade of the stellate ganglion and the addition of a second antiarrhythmic (lidocaine) should be considered. In patients refractory to these measures, with advanced heart failure, general anaesthesia with intubation and the establishment of a haemodynamic circulatory support should be considered. Ablation, performed early, appears to be superior in terms of mortality and reduction of future shocks compared with titration of antiarrhythmics.

cardiac & cardiovascular systems
Radiation therapy for ventricular arrhythmias

Xingzhou Liulu,Poornima Balaji,Jeffrey Barber,Kasun De Silva,Tiarne Murray,Andrew Hickey,Timothy Campbell,Jill Harris,Harriet Gee,Verity Ahern,Saurabh Kumar,Eric Hau,Pierre C Qian

DOI: https://doi.org/10.1111/1754-9485.13662

2024-05-04

Journal of Medical Imaging and Radiation Oncology

Abstract:Ventricular arrhythmias (VA) can be life‐threatening arrhythmias that result in significant morbidity and mortality. Catheter ablation (CA) is an invasive treatment modality that can be effective in the treatment of VA where medications fail. Recurrence occurs commonly following CA due to an inability to deliver lesions of adequate depth to cauterise the electrical circuits that drive VA or reach areas of scar responsible for VA. Stereotactic body radiotherapy is a non‐invasive treatment modality that allows volumetric delivery of energy to treat circuits that cannot be reached by CA. It overcomes the weaknesses of CA and has been successfully utilised in small clinical trials to treat refractory VA. This article summarises the current evidence for this novel treatment modality and the steps that will be required to bring it to the forefront of VA treatment.

radiology, nuclear medicine & medical imaging
[The prevalence of sleep-related breathing disorders in patients with implanted cardioverter-defibrillators. The effect on the incidence and circadian distribution of malignant ventricular tachyarrhythmias].

H. Schieffer,J. Fichter,J. Jung,G. Sybrecht,D. Bauer,A. Heisel,R. Fries

Abstract:OBJECTIVE To determine the prevalence of sleep-related breathing disorders (SRBD) on patients who, because of malignant ventricular tachyarrhythmias associated with cardiac disease, have an implanted cardioverter-defibrillator (ICD). It was also investigated whether the frequency and circadian distribution of spontaneous ventricular tachycardia and (or) fibrillation (VTF) can be influenced by SRBD. PATIENTS AND METHODS 29 consecutive ICD patients (28 men, one woman; mean age 64 +/- 8 years) were investigated by multifunction recordings. 22 patients had coronary heart disease, and seven dilated cardiomyopathy. For each patient the number of VIF episodes per month were recorded, as well as the percentage distribution of the episodes during the day per hour and after grouping into four time periods. RESULTS SRBDs were recorded in 13 of the 29 patients (45%) (apnoea-hypopnea index [AHI] > 10). The other 16 patients had normal findings (AHI < or = 10). Mean frequency of the registered VTF attacks was similar in both groups (0.41/month with AHI < or = 10 vs 0.44/month with AHI > 10; difference not statistically significant). Averaged percentage distribution pattern showed a maximum frequency in both groups between 6 o'clock and 12 o'clock a.m. There was no significant increase of VTF during the night (10 o'clock p.m.-6 o'clock a.m.) in the group with SRBD (19% with AHI > 10 vs 18.2% with ATF < or = 10; difference not significant). CONCLUSION There was a high prevalence of SRBD in the patients with ICD and underlying cardiac disease. No influence of SRBD on frequency and circadian distribution of VTF was demonstrated in patients with ICD during long-term observation.

Medicine

Treatment of malignant ventricular arrhythmias in man with an implanted automatic defibrillator.

Use of the automatic implantable cardioverter-defibrillator in the treatment of malignant ventricular tachyarrhythmias

Potential Maintenance Mechanism in Atrial Fibrillation Patients Subject to Different Treatment Procedures: A Preliminary Study Based on a Human Atrial Model

[The implantable automatic cardioverter-defibrillator]

The development of the extravascular defibrillator with substernal lead placement: A new Frontier for device-based treatment of sudden cardiac arrest

Ventricular Arrhythmias in Ischemic Cardiomyopathy—New Avenues for Mechanism-Guided Treatment

First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial

Cause and Treatment of Inappropriate Therapy of Implantable Cardioverter Defibrillators

Management of ventricular tachycardia in patients with ischaemic cardiomyopathy: contemporary armamentarium

Transatlantic differences in the use of implantable cardioverter defibrillators in arrhythmogenic right ventricular cardiomyopathy

Subcutaneous ICD Implantation and Catheter Ablation: A Step-Planned Approach for Ventricular Tachycardia Management in ARVC

Tenth Annual Scientific Congress

A cost-effective emergency room laboratory.

Prognosis in patients with coronary heart disease and ventricular arrhythmias received implantable cardioverter defibrillators

Use of class IC antiarrhythmic drugs in patients with structural heart disease and implantable cardioverter defibrillator

Defibrillator implantation for the primary prevention of sudden cardiac death in patients with chronic heart failure

Radiofrequency Ablation of Ventricular Fibrillation and Multiple Right and Left Atrial Tachycardia in a Patient with Brugada Syndrome

Anesthetic management of a patient with celiac disease.

The point on the treatment of arrhythmic storm

Radiation therapy for ventricular arrhythmias

[The prevalence of sleep-related breathing disorders in patients with implanted cardioverter-defibrillators. The effect on the incidence and circadian distribution of malignant ventricular tachyarrhythmias].